ABUS
Income statement / Annual
Last year (2023), Arbutus Biopharma Corporation's total revenue was $18.14 M,
a decrease of 53.51% from the previous year.
In 2023, Arbutus Biopharma Corporation's net income was -$72.85 M.
See Arbutus Biopharma Corporation’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$18.14 M
|
$39.02 M
|
$10.99 M
|
$6.91 M
|
$6.01 M
|
$5.90 M
|
$10.70 M
|
$1.50 M
|
$24.87 M
|
$15.00 M
|
| Cost of Revenue |
$73.70 M |
$1.43 M |
$1.75 M |
$47.48 M |
$57.60 M |
$57.90 M |
$62.70 M |
$61.30 M |
$51.51 M |
$38.70 M |
| Gross Profit |
-$55.56 M |
$37.59 M |
$9.24 M |
-$40.57 M |
-$51.59 M |
-$52.00 M |
-$52.00 M |
-$59.80 M |
-$26.63 M |
-$23.70 M |
| Gross Profit Ratio |
-3.06 |
0.96 |
0.84 |
-5.87 |
-8.58 |
-8.81 |
-4.86 |
-39.87 |
-1.07 |
-1.58 |
| Research and Development
Expenses |
$73.70 M
|
$84.41 M
|
$65.50 M
|
$47.48 M
|
$57.60 M
|
$57.90 M
|
$62.70 M
|
$61.30 M
|
$51.51 M
|
$38.70 M
|
| General & Administrative
Expenses |
$22.48 M
|
$17.83 M
|
$17.14 M
|
$14.72 M
|
$17.73 M
|
$16.00 M
|
$16.10 M
|
$39.40 M
|
$26.44 M
|
$8.70 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$22.48 M
|
$17.83 M
|
$17.14 M
|
$14.72 M
|
$17.73 M
|
$16.00 M
|
$16.10 M
|
$39.40 M
|
$26.44 M
|
$8.70 M
|
| Other Expenses |
-$73.63 M |
$2.23 M |
$1.87 M |
$1.98 M |
$2.03 M |
$7.30 M |
$2.20 M |
$2.50 M |
-$770,000.00 |
-$5.80 M |
| Operating Expenses |
$22.54 M |
$102.24 M |
$82.64 M |
$64.18 M |
$77.36 M |
$76.10 M |
$80.80 M |
$101.80 M |
$78.53 M |
$47.90 M |
| Cost And Expenses |
$96.24 M |
$102.24 M |
$82.64 M |
$64.18 M |
$77.36 M |
$76.10 M |
$80.80 M |
$101.80 M |
$78.53 M |
$47.90 M |
| Interest Income |
$5.69 M |
$2.19 M |
$127,000.00 |
$741,000.00 |
$2.11 M |
$3.00 M |
$1.54 M |
$1.39 M |
$674,000.00 |
$853,000.00 |
| Interest Expense |
$459,000.00 |
$1.73 M |
$2.86 M |
$4.01 M |
$2.11 M |
$200,000.00 |
$261,000.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$1.40 M
|
$1.43 M
|
$1.75 M
|
$1.98 M
|
$2.03 M
|
$2.18 M
|
$2.03 M
|
$1.09 M
|
$589,000.00
|
$500,000.00
|
| EBITDA |
-$70.99 M
|
-$61.86 M
|
-$71.64 M
|
-$57.81 M
|
-$147.32 M
|
-$58.95 M
|
-$106.45 M
|
-$488.07 M
|
-$76.72 M
|
-$32.44 M
|
| EBITDA Ratio |
-3.91 |
-1.56 |
-6.51 |
-8.26 |
-14.9 |
-10.73 |
-2.55 |
194.73 |
-1.19 |
-2.16 |
| Operating Income Ratio
|
-4.31
|
-1.68
|
-6.69
|
-8.36
|
-23.97
|
-15.22
|
-10.36
|
-327.73
|
-4.11
|
-2.2
|
| Total Other
Income/Expenses Net |
$5.25 M
|
$444,000.00
|
-$2.73 M
|
-$5.94 M
|
-$22.48 M
|
$28.44 M
|
$2.20 M
|
$2.47 M
|
$25.02 M
|
-$5.40 M
|
| Income Before Tax |
-$72.85 M |
-$65.01 M |
-$76.25 M |
-$63.75 M |
-$166.38 M |
-$61.40 M |
-$108.70 M |
-$489.10 M |
-$77.31 M |
-$38.70 M |
| Income Before Tax Ratio
|
-4.02
|
-1.67
|
-6.94
|
-9.22
|
-27.68
|
-10.41
|
-10.16
|
-326.07
|
-3.11
|
-2.58
|
| Income Tax Expense |
$0.00 |
$4.44 M |
$1.10 M |
$1.47 M |
-$12.66 M |
-$4.30 M |
-$24.30 M |
-$105.00 M |
-$16.19 M |
$100,000.00 |
| Net Income |
-$72.85 M |
-$69.46 M |
-$77.35 M |
-$65.21 M |
-$153.72 M |
-$57.10 M |
-$84.40 M |
-$384.10 M |
-$61.12 M |
-$38.80 M |
| Net Income Ratio |
-4.02 |
-1.78 |
-7.04 |
-9.43 |
-25.57 |
-9.68 |
-7.89 |
-256.07 |
-2.46 |
-2.59 |
| EPS |
-0.44 |
-0.46 |
-0.73 |
-0.86 |
-2.69 |
-1.03 |
-1.54 |
-7.24 |
-1.34 |
-1.8 |
| EPS Diluted |
-0.44 |
-0.46 |
-0.73 |
-0.86 |
-2.69 |
-1.03 |
-1.54 |
-7.24 |
-1.34 |
-1.73 |
| Weighted Average Shares
Out |
$165.96 M
|
$150.94 M
|
$106.24 M
|
$75.84 M
|
$57.09 M
|
$55.30 M
|
$54.69 M
|
$53.05 M
|
$45.45 M
|
$21.58 M
|
| Weighted Average Shares
Out Diluted |
$165.96 M
|
$150.94 M
|
$106.24 M
|
$75.84 M
|
$57.09 M
|
$55.30 M
|
$54.72 M
|
$53.05 M
|
$45.46 M
|
$22.44 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
